Novo Nordisk reported Q2 2026 adjusted operating profit of DKK 33.4 billion, an 11% increase at constant exchange rates (CER), driven by GLP-1 volume growth. Reported sales rose 3% at CER to DKK 78.5 billion, though growth was negatively impacted by a DKK 2.6 billion rebate provision reversal from Q2 2025 and non-cash impairment charges of DKK 6.3 billion in Q2 2026 related to pipeline assets including monlunabant. The company raised its full-year adjusted sales and operating profit growth outlook to 0% to -6% at CER, citing increased expectations for GLP-1 product sales. Commercial highlights include Wegovy pill prescriptions exceeding 265,000 weekly in the US and launches of Wegovy HD and new formulations in international markets. Novo Nordisk A/S is a global healthcare company specializing in diabetes care, obesity treatment, and rare disease therapies.